“showed a trend”

A comparison of 5 μ g/mL imatinib with 10 μ g/mL albendazole also showed a trend toward higher efficacy for imatinib, with complete protoscoleces death occurring on Days 30 and 33, respectively ( p > 0.05).

Surgical duration ≥120 min showed a trend toward increased risk (OR = 2.12, p = 0.050), warranting caution in prolonged cases.

Comparing the regional + 10% to the 50% threshold showed a trend toward higher sensitivity (+12.0%, p = .05) and PPV (+1.0%, p = .05).

The body fluid recovery ratio was 24.0 ± 6.0% in the CW, which showed a trend toward being lower compared to the W trial (42.9 ± 5.4%; mean difference: −20.66%, 95% CI: [−41.40, 0.08]%, p = 0.050), and was significantly less than in the EW (45.4 ± 8.0%; mean difference: −22.96%, 95% CI: [−43.24, −2.68]%, p = 0.021) and ECW (47.8 ± 6.6%; mean difference: −25.53%, 95% CI: [−46.27, −4.79]%, p = 0.010) trials ( Figure 1 B). 3.2.

FOXP3 + expression showed a trend toward a significant association with more favorable OS but not PFS (OS: p = 0.05, PFS: p = 0.07) (Fig. 5 , Table 5 ) using univariate analysis .

No differences were recorded in any of the five complexes between cyanotic and acyanotic CHD cases. The correlation analyses showed a trend for positive correlation between the S. mutans counts and the number of decayed teeth CHD cases (correlation coefficient = 0.26, p = 0.05) and among the control (correlation coefficient = 0.13, p = 0.29).

Later age of symptom onset (70+ years) was associated with lower odds of genetic testing completion (OR 0.23; 95% CI 0.12–0.43; P < 0.001) compared to the reference group (10–19 years), while early symptom onset (0–9 years) showed a trend toward higher odds of genetic testing completion that approached but did not reach statistical significance (OR 1.53; 95% CI 1–2.37; P = 0.05).

17 We found that blood leukocyte count showed a trend toward decreased numbers after 2 weeks (b = −0.5, SE = 0.26, p = 0.05, q = 0.10) and after the recovery phase (b = −0.75, SE = 0.26, p = 0.006, q = 0.02) in the T2D group, while no changes were observed in the control group (Table S4).

In this study, in the LD, the relative mRNA levels of the FAS and H-FABP genes showed a trend toward 4-year-old>2-year-old >3-year-old (p<0.05), while PPARγ expression was highest at 2-year-old (p<0.05).

With the prolongation of storage time, the solubility of preserved egg white gel at 3 storage temperatures showed a trend of first decreasing and then increasing in S1 ( P < 0.05), the solubility in S4 increased first and then decreased ( P < 0.05), and there was no obvious change trend in S2 and S3 parts.

More exposure to cytotoxic chemotherapy before osimertinib showed a trend toward systemic PD (20.0% vs. 37.9%, p = 0.05, Table 2 ).

In adjusted analysis, we found that patients discharged from the cardiac floor showed a trend toward decreased readmission (p-value > 0.05 but < 0.10) and that season of discharge was associated with readmission (Table 2 ).

In subgroup analysis, hypertensive patients with high MDA were significantly older ( p = 0.03) and showed a trend towards higher systolic BP ( p = 0.05) compared to those with low MDA.

Compared with the CT treatment, DMSO showed a trend towards the decreased mRNA expression of genes PI3KAP1 , MAP3K5 , Fos and BCL2L1 ( Figure 3 A–D, p < 0.05), while PKCOS showed a trend towards the increased expression of genes PI3KAP1 , MAP3K5 and Fos and the restored mRNA expression of BCL2L1 ( p < 0.05).

When HT-29 cells were treated for 24 h with a low dose, bacterial invasion resulted in being about 2.5 times higher with respect to control cells, whereas cells pre-treated with NP high dose showed a trend to decreased invasion (245.5 ± 13 for 1 μg/cm 2 and 53 ± 12 for 20 μg/cm 2 , respectively, * p < 0.05). 3.4.

Association with cognitive function: Higher NT-proBNP levels were associated with significantly lower DSST scores (β = −0.12; 95% CI = −0.21, −0.03; Table 4 , Model 2) and showed a trend of association with worst Stroop scores ( p = 0.05 and 0.01 in Model 1 and 2, respectively).

Change in therapeutic strategy in cases of unfavorable results led to 50.0% restoration or symptom control and showed a trend towards favorable outcome ( p = 0.05).

Scores in hepatology, as well as biliary and pancreatic study, showed a trend toward improvement ( p >0.05).

Patients with patch-closed hernia showed a trend to increased mortality in comparison to stitch-closed CDH (patch mortality 21.7% vs. stitch mortality 5.1%, p = 0.05).

With respect to the lipid profile, although total cholesterol and high-density lipoprotein (HDL) levels showed a trend toward variation between the groups, these differences did not reach statistical significance ( P > 0.05) [ Table 3 ].

In group 3, the collagen 3 concentration and αSMA-positive cell counts remained high but showed a trend towards decrease when compared to group 2 ( P > 0.05).

In addition, the recurrent course showed a trend of being more frequent than acute and chronic in BD vs. non-BD subjects ( p = 0.05).

Similarly, in the Pembrolizumab + Docetaxel group, non-responders showed a trend towards increased EV PD-L1 in comparison to responders ( p = 0.050) (Fig. 3 E) while no differences were observed in the Docetaxel treated patients (Fig. 3 F).

Donors with perivascular cuffs showed a trend ( P = 0.050) toward enrichment of this genotype.

Although there was no statistically significant difference between the honey group and the model group, which also showed a trend of improvement ( Figure 1(C–E) , p < 0.05).